JMT202
Monoclonal antibody
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07140809 NCT07140809 · Hypertriglyceridemia Registry: NCT07140809 | 1/2 | The incidence and severity of TEAE (Day 1 to 99); Number of participants with vital sign abnormalities (Day 1 to 99); Number of participants with physical examination abnormalities (Day 1 to 99); Number of participants with laboratory tests abnormalities (Day 1 to 99); Number of participants with 12-lead electrocardiogram abnormalities (Day 1 to 99); Number of participants with injection site reactions abnormalities (Day 1 to 63) 2026-07-31 | In progress: primary completion was expected 31 Jul 2026; results not posted | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Hypertriglyceridemia: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| JMT202: this drug | Phase 1/2 | Monoclonal antibody | β-Klotho (KLB) | not yet graded | No reviewed efficacy summary in this indication | |
| Omega-3-Acid Ethyl Esters A (Omtryg) | ApprovedUS marketing discontinued | Small molecule | Triglyceride synthesis / VLDL | not yet graded | No reviewed efficacy summary in this indication | |
| Rosuvastatin | Approved | Small molecule | HMG-CoA reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Olezarsen (Tryngolza) | Phase 3 | RNA / oligonucleotide | APOC3 | Reliable signal | NCT05552326: Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001) NCT05079919: Placebo-adjusted LSM % change in fasting triglycerides at 6 months (CORE-TIMI 72a, NCT05079919, n=617): olezarsen 50 mg -62.9% (95% CI -72.2 to -53.6, p<0.001); olezarsen 80 mg -72.2% (95% CI -81.4 to -63.1, p<0.001). | |
| Pemafibrate (Parmodia) | Phase 3 | Small molecule | PPAR-alpha | Reliable signal | NCT04998981: n=344 randomized (of 353 enrolled per CT.gov). % change in fasting TG from baseline at Week 12: -34.1% (pemafibrate 0.2mg/d), -44.0% (pemafibrate 0.4mg/d), -30.5% (fenofibrate 200mg/d), +6.5% (placebo); 0.4mg/d vs placebo p<0.0001, vs fenofibrate p=0.0083. | |
| Plozasiran (Redemplo) | Phase 3 | RNA / oligonucleotide | APOC3 | Partial signal | NCT06347003: Primary endpoint met: triglyceride reduction vs placebo, and all prespecified secondary endpoints (SHASTA-3, Arrowhead, 2026-07-22). | |
| Pravafenix | Phase 3(overall) | Small molecule | HMG-CoA reductase / PPAR-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Saroglitazar (Lipaglyn) | Phase 3(overall) | Small molecule | PPAR-alpha/PPAR-gamma | not yet graded | No reviewed efficacy summary in this indication | |
| BW-00112 | Phase 2 | RNA / oligonucleotide | ANGPTL3 | not yet graded | No reviewed efficacy summary in this indication | |
| EDP167 | Phase 2 | RNA / oligonucleotide | ANGPTL3 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-7249 | Phase 2 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| ION775 | Phase 2 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| MAR001 | Phase 2 | Monoclonal antibody | ANGPTL4 | Weak signal | Featured results are safety only in this race | |
| RBD5044 | Phase 2 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| SYH2070 | Phase 2(overall) | RNA / oligonucleotide | ANGPTL3 | not yet graded | No reviewed efficacy summary in this indication | |
| Tipelukast | Phase 2 | Small molecule | Cysteinyl leukotriene receptor 1 (CysLT1) / PDE3 / PDE4 / 5-lipoxygenase | Weak signal | NCT02681055: Primary 1, cholesterol efflux capacity change from baseline to week 12: mean -0.013 (SD 0.1022) percentage of cholesterol. Primary 2, serum triglyceride change from baseline to week 8: mean -21.67 (SD 27.89) mg/dL. Single arm (n=19), no comparator; CT.gov posted results. | |
| TLC-2716 | Phase 2 | Small molecule | Liver X receptor (LXR) | not yet graded | No reviewed efficacy summary in this indication | |
| RN0361 | Phase 1/2 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| ALN-APOC3 | Phase 1(overall) | RNA / oligonucleotide | Apolipoprotein C-III (APOC3) | not yet graded | No reviewed efficacy summary in this indication | |
| ISH0688 | Phase 1 | Protein / enzyme therapeutic | FGF21 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Kylo-12 | Phase 1 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| VERVE-201 | Phase 1 | Gene therapy / editing | ANGPTL3 gene (hepatocyte genomic DNA) | not yet graded | No reviewed efficacy summary in this indication | |
| Omega-3-Carboxylic Acids (Epanova) | Discontinued | Small molecule | Peroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptor | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.